Literature DB >> 11796813

25 years of HIV in New York City: lessons from surveillance.

.   

Abstract

Entities:  

Mesh：

Year:  2001        PMID： 11796813      PMCID： PMC3455868          DOI： 10.1093/jurban/78.4.669

Source DB:  PubMed          Journal:  J Urban Health        ISSN： 1099-3460            Impact factor:   3.671


× No keyword cloud information.
  16 in total

1.  HIV incidence among injection drug users in New York City, 1992-1997: evidence for a declining epidemic.

Authors:  D C Des Jarlais; M Marmor; P Friedmann; S Titus; E Aviles; S Deren; L Torian; D Glebatis; C Murrill; E Monterroso; S R Friedman
Journal:  Am J Public Health       Date:  2000-03       Impact factor: 9.308

2.  Economic and geographic diversity in AIDS incidence among HIV exposure groups in New York City: 1983 to 1995.

Authors:  E J Fordyce; R Shum; T P Singh; S Forlenza
Journal:  AIDS Public Policy J       Date:  1998

3.  Improved survival among HIV-infected individuals following initiation of antiretroviral therapy.

Authors:  R S Hogg; K V Heath; B Yip; K J Craib; M V O'Shaughnessy; M T Schechter; J S Montaner
Journal:  JAMA       Date:  1998-02-11       Impact factor: 56.272

4.  Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men--New York City and California.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1981-07-03       Impact factor: 17.586

5.  Screening test for HTLV-III (AIDS agent) antibodies. Specificity, sensitivity, and applications.

Authors:  S H Weiss; J J Goedert; M G Sarngadharan; A J Bodner; R C Gallo; W A Blattner
Journal:  JAMA       Date:  1985-01-11       Impact factor: 56.272

6.  Declining HIV/AIDS mortality in New York City.

Authors:  M A Chiasson; L Berenson; W Li; S Schwartz; T Singh; S Forlenza; B A Mojica; M A Hamburg
Journal:  J Acquir Immune Defic Syndr       Date:  1999-05-01       Impact factor: 3.731

7.  Intersecting epidemics--crack cocaine use and HIV infection among inner-city young adults. Multicenter Crack Cocaine and HIV Infection Study Team.

Authors:  B R Edlin; K L Irwin; S Faruque; C B McCoy; C Word; Y Serrano; J A Inciardi; B P Bowser; R F Schilling; S D Holmberg
Journal:  N Engl J Med       Date:  1994-11-24       Impact factor: 91.245

8.  Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.

Authors:  E M Connor; R S Sperling; R Gelber; P Kiselev; G Scott; M J O'Sullivan; R VanDyke; M Bey; W Shearer; R L Jacobson
Journal:  N Engl J Med       Date:  1994-11-03       Impact factor: 91.245

9.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

Authors:  F Barré-Sinoussi; J C Chermann; F Rey; M T Nugeyre; S Chamaret; J Gruest; C Dauguet; C Axler-Blin; F Vézinet-Brun; C Rouzioux; W Rozenbaum; L Montagnier
Journal:  Science       Date:  1983-05-20       Impact factor: 47.728

10.  New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes.

Authors:  R S Janssen; G A Satten; S L Stramer; B D Rawal; T R O'Brien; B J Weiblen; F M Hecht; N Jack; F R Cleghorn; J O Kahn; M A Chesney; M P Busch
Journal:  JAMA       Date:  1998-07-01       Impact factor: 56.272
View more
  5 in total

1.  Trends in predictors of death due to HIV-related causes among persons living with AIDS in New York City: 1993-2001.

Authors:  Denis Nash; Monica Katyal; Sarita Shah
Journal:  J Urban Health       Date:  2005-10-19       Impact factor: 3.671

2.  Hepatitis C virus prevalence and estimated incidence among new injectors during the opioid epidemic in New York City, 2000-2017: Protective effects of non-injecting drug use.

Authors:  Don C Des Jarlais; K Arasteh; J Feelemyer; C McKnight; David M Barnes; David C Perlman; A Uuskula; H L F Cooper; Susan Tross
Journal:  Drug Alcohol Depend       Date:  2018-09-12       Impact factor: 4.492

3.  Potential geographic "hotspots" for drug-injection related transmission of HIV and HCV and for initiation into injecting drug use in New York City, 2011-2015, with implications for the current opioid epidemic in the US.

Authors:  D C Des Jarlais; H L F Cooper; K Arasteh; J Feelemyer; C McKnight; Z Ross
Journal:  PLoS One       Date:  2018-03-29       Impact factor: 3.240

4.  PROMISE (Program Refinements to Optimize Model Impact and Scalability based on Evidence): a cluster-randomised, stepped-wedge trial assessing effectiveness of the revised versus original Ryan White Part A HIV Care Coordination Programme for patients with barriers to treatment in the USA.

Authors:  Mary K Irvine; Bruce Levin; McKaylee M Robertson; Katherine Penrose; Jennifer Carmona; Graham Harriman; Sarah L Braunstein; Denis Nash
Journal:  BMJ Open       Date:  2020-07-27       Impact factor: 2.692

5.  Geographic distribution of risk ("Hotspots") for HIV, HCV, and drug overdose among persons who use drugs in New York City: the importance of local history.

Authors:  D C Des Jarlais; C McKnight; K Arasteh; J Feelemyer; Zev Ross; H L F Cooper
Journal:  Harm Reduct J       Date:  2019-09-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.